# PPI-amoxicillin for H. Pylori Treatment

> **NCT05014685** · PHASE4 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 732 (estimated)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Rabeprazole
- **DRUG:** Bismuth potassium citrate
- **DRUG:** Metronidazole
- **DRUG:** Amoxicillin

## Key facts

- **NCT ID:** NCT05014685
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-20
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 732 (ESTIMATED)
- **Last updated:** 2021-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05014685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05014685, "PPI-amoxicillin for H. Pylori Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05014685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*